This content is from: Research
Health Care – Pharmaceuticals/Speciality: 2012 Third
Reclaiming third place, after two years in the runner-up position, is David Steinberg of Deutsche Bank Securities.
| Reclaiming third place, after two years in the runner-up position, is David Steinberg of Deutsche Bank Securities. “His longevity following the sector is his biggest asset — he has seen and heard it all,” says one loyalist. Steinberg covers 16 stocks, one more than last year. In September 2011 the San Francisco–based analyst launched coverage of Akorn — a vaccine and injectable-medicines manufacturer headquartered in Lake Forest, Illinois — with a buy rating, at $8.48, largely on valuation. In July, after the shares had soared 75.7 percent, to $14.90, he downgraded them to hold, citing disappointing sales of Akorn’s generic antibiotic vancomycin hydrochloride, among other factors. The stock had slid 7.1 percent, to $13.84, by the end of August. Steinberg’s sector outlook is mixed: Fundamentals still look attractive for several large-cap companies, while others have been negatively affected by their exposure to Europe. Stock picking is essential, he says. RUNNER(S)-UP Kenneth Cacciatore Cowen and Co. Marc Goodman UBS David Risinger Morgan Stanley Christopher Schott J. P. Morgan |